Table 1. Characteristics of patients,... | American Society of Hematology

Table 1.

Characteristics of patients, donors, and grafts

Variable	All		Locatelli et al (2017)⁴		Additional 133 patients		P value
Variable	No.	%/Range	No.	%/Range	No.	%/Range	P value
	213	100	80		133
Sex
Male	105	49	55	69	50	37.5	<.001
Female	108	51	25	31	83	62.5
Age at transplant, median (range), y	9.5	0.7-24.6	9.7	0.9-20.9	9.3	0.7-24.6	N.S.
ALL/AML	152/61	66/34	56/24	70/30	96/37	72/28	N.S.
ALL phenotype
BCP	124	81.5	41	73	83	87	.02
T	26	17	15	27	11	11
Mixed	2	1.5	0		2	2
Disease status at transplantation
ALL
CR1	40	19	15	19	25	19	.02
CR2	85	40	37	46	48	36
≥CR3	27	12	4	5	23	17
Pre-HSCT MRD⁺∗	11	7
AML
CR1	40	19	16	20	24	18	N.S.
CR2	21	10	8	10	13	10
Pre-HSCT MRD⁺†	7	11.5
Conditioning regimen							N.S.
TBI + TT + Flu	100	47	40	50	60	45
TBI + TT + L-PAM	61	28.5	20	25	41	31
Bu + TT + Flu	13	6	13	16	0
Bu + Cy + L-PAM	21	10	7	9	14	10.5
Others	18	8.5	0		18	13.5
CMV serology (donor/recipient)							N.S.
Neg/neg	12	6	5	6	7	5
Neg/pos	20	9	7	9	13	10
Pos/neg	17	8	11	14	6	4.5
Pos/pos	164	77	57	71	107	80.5
Donor characteristics
Age, y	34.5	19-59	41.5	27-55	38	19-59	.01
Type of donor							.01
Mother	109	51	46	58	63	47.5
Father	92	43	34	42	58	43.5
Brother/sister	12	6	0		12	9
Sex mismatch	118	55	49	61	69	52	N.S.
Female donor → male recipient	75 (/118)	64	35 (/49)	71	40 (/69)	58	N.S.
NK alloreactivity (KIR/KIR-L model) yes/no	75/127‡	37/63	36/44	45/55	39/83‡	32/68	N.S.
KIR genotype A/A vs B/X	47/155‡	23/77	16/64	20/80	31/91‡	25/75	N.S.
Donor B content value 0-1 vs ≥2	122/80‡	60/40	44/36	55/45	79/43‡	65/35	N.S.
Donor KIR2DS1 “educated and useful”‖ yes/no	62/140‡	30/70	28/52	35/65	34/88‡	28/72	N.S.
Cell dose infused, median (range)
CD34⁺ cells × 10⁶/kg	14.8	6.0- 40.4	13.9	6.0-40.4	15.53	6.1-33.8	N.S.
αβ⁺ T cells × 10⁶/kg	0.04	0.001-0.099	0.047	0.002-0.099	0.033	0.001-0.099	.005
γδ⁺ T cells × 10⁶/kg	7.9	0.6-60.8	8.1	0.86-56.7	8.2	0.6-60.8	N.S.
NK cells × 10⁶/kg	33.1	3.84-203.0	34.6	3.84-146.1	32.8	5.4-203.0	N.S.

Variable	All		Locatelli et al (2017)⁴		Additional 133 patients		P value
Variable	No.	%/Range	No.	%/Range	No.	%/Range	P value
	213	100	80		133
Sex
Male	105	49	55	69	50	37.5	<.001
Female	108	51	25	31	83	62.5
Age at transplant, median (range), y	9.5	0.7-24.6	9.7	0.9-20.9	9.3	0.7-24.6	N.S.
ALL/AML	152/61	66/34	56/24	70/30	96/37	72/28	N.S.
ALL phenotype
BCP	124	81.5	41	73	83	87	.02
T	26	17	15	27	11	11
Mixed	2	1.5	0		2	2
Disease status at transplantation
ALL
CR1	40	19	15	19	25	19	.02
CR2	85	40	37	46	48	36
≥CR3	27	12	4	5	23	17
Pre-HSCT MRD⁺∗	11	7
AML
CR1	40	19	16	20	24	18	N.S.
CR2	21	10	8	10	13	10
Pre-HSCT MRD⁺†	7	11.5
Conditioning regimen							N.S.
TBI + TT + Flu	100	47	40	50	60	45
TBI + TT + L-PAM	61	28.5	20	25	41	31
Bu + TT + Flu	13	6	13	16	0
Bu + Cy + L-PAM	21	10	7	9	14	10.5
Others	18	8.5	0		18	13.5
CMV serology (donor/recipient)							N.S.
Neg/neg	12	6	5	6	7	5
Neg/pos	20	9	7	9	13	10
Pos/neg	17	8	11	14	6	4.5
Pos/pos	164	77	57	71	107	80.5
Donor characteristics
Age, y	34.5	19-59	41.5	27-55	38	19-59	.01
Type of donor							.01
Mother	109	51	46	58	63	47.5
Father	92	43	34	42	58	43.5
Brother/sister	12	6	0		12	9
Sex mismatch	118	55	49	61	69	52	N.S.
Female donor → male recipient	75 (/118)	64	35 (/49)	71	40 (/69)	58	N.S.
NK alloreactivity (KIR/KIR-L model) yes/no	75/127‡	37/63	36/44	45/55	39/83‡	32/68	N.S.
KIR genotype A/A vs B/X	47/155‡	23/77	16/64	20/80	31/91‡	25/75	N.S.
Donor B content value 0-1 vs ≥2	122/80‡	60/40	44/36	55/45	79/43‡	65/35	N.S.
Donor KIR2DS1 “educated and useful”‖ yes/no	62/140‡	30/70	28/52	35/65	34/88‡	28/72	N.S.
Cell dose infused, median (range)
CD34⁺ cells × 10⁶/kg	14.8	6.0- 40.4	13.9	6.0-40.4	15.53	6.1-33.8	N.S.
αβ⁺ T cells × 10⁶/kg	0.04	0.001-0.099	0.047	0.002-0.099	0.033	0.001-0.099	.005
γδ⁺ T cells × 10⁶/kg	7.9	0.6-60.8	8.1	0.86-56.7	8.2	0.6-60.8	N.S.
NK cells × 10⁶/kg	33.1	3.84-203.0	34.6	3.84-146.1	32.8	5.4-203.0	N.S.

Data are given for the whole cohort and comparison between 80 already described patients and 133 new ones.

BCP, B-cell precursor; Bu, busulfan; CMV, cytomegalovirus; Cy, cyclophosphamide; Flu, fludarabine; L-PAM, melphalan; Neg, negative; N.S., not significant; Pos, positive; TT, thiotepa.

∗

MRD⁺ if >10⁻⁴.

†

MRD⁺ if >10⁻³.

‡

Data from 122 of 133 donors.

View Large

This Feature Is Available To Subscribers Only